Latest News

Given the increasing prevalence of Alzheimer’s disease and a staggering number of people with dementia who are undiagnosed, this author discusses five essential keys for radiologists and their colleagues to facilitate earlier detection, precision care treatment and monitoring to help ensure timely care and intervention.

For patients with small cell lung cancer (SCLC), there was a 40 percent improvement in cognitive failure-free survival (CFFS) with brain MRI alone in comparison to the combination of brain MRI and prophylactic cranial irradiation (PCI), according to research presented at the ASTRO conference.

Constant grumbling from an attending radiologist about the road ahead may be a sign that his or her best teaching years may be in the rear-view mirror.

Catch up on a variety of FDA news in radiology from the past week.

Catch up on the top radiology content of the past week.

In a recent interview, Shadpour Demehri, MD, discussed new research examining connections between deep learning assessment of bone mineral density on chest CT, brain MRI data and the potential for enhanced risk stratification in patients with diabetes.

Catch up on the top AI-related news and research in radiology over the past month.

A deep learning model developed for predicting BI-RADS assessments from dynamic contrast-enhanced (DCE) breast MRI had over a 14 percent lower AUC than radiologist evaluation in external validation testing.

While better imaging may reduce the need for additional diagnostic tests, it may also eliminate the reimbursement that comes with those additional tests.

The CARE Chest X-Ray (CXR) Triage software reportedly bolsters consistent flagging of suspicious chest X-rays for lung collapse and pneumomediastinum across reviewing readers of different experience levels.

In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.

Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.

Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.